1. Home
  2. GROY vs LCTX Comparison

GROY vs LCTX Comparison

Compare GROY & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GROY
  • LCTX
  • Stock Information
  • Founded
  • GROY 2020
  • LCTX 1990
  • Country
  • GROY Canada
  • LCTX United States
  • Employees
  • GROY N/A
  • LCTX N/A
  • Industry
  • GROY
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GROY
  • LCTX Health Care
  • Exchange
  • GROY Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • GROY 322.2M
  • LCTX 274.0M
  • IPO Year
  • GROY 2021
  • LCTX N/A
  • Fundamental
  • Price
  • GROY $3.16
  • LCTX $1.21
  • Analyst Decision
  • GROY Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • GROY 4
  • LCTX 5
  • Target Price
  • GROY $4.58
  • LCTX $4.20
  • AVG Volume (30 Days)
  • GROY 2.3M
  • LCTX 1.5M
  • Earning Date
  • GROY 08-06-2025
  • LCTX 08-12-2025
  • Dividend Yield
  • GROY N/A
  • LCTX N/A
  • EPS Growth
  • GROY N/A
  • LCTX N/A
  • EPS
  • GROY N/A
  • LCTX N/A
  • Revenue
  • GROY $12,376,000.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • GROY $84.26
  • LCTX N/A
  • Revenue Next Year
  • GROY $50.03
  • LCTX $244.95
  • P/E Ratio
  • GROY N/A
  • LCTX N/A
  • Revenue Growth
  • GROY 90.37
  • LCTX 76.43
  • 52 Week Low
  • GROY $1.16
  • LCTX $0.37
  • 52 Week High
  • GROY $3.26
  • LCTX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • GROY 64.88
  • LCTX 62.25
  • Support Level
  • GROY $2.89
  • LCTX $1.15
  • Resistance Level
  • GROY $3.09
  • LCTX $1.29
  • Average True Range (ATR)
  • GROY 0.17
  • LCTX 0.08
  • MACD
  • GROY -0.01
  • LCTX 0.02
  • Stochastic Oscillator
  • GROY 79.17
  • LCTX 72.22

About GROY Gold Royalty Corp.

Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: